| Literature DB >> 31458795 |
Vishwesh Mishra1, Natesan Thirupathi1.
Abstract
The reactions ofEntities:
Year: 2018 PMID: 31458795 PMCID: PMC6644913 DOI: 10.1021/acsomega.8b00782
Source DB: PubMed Journal: ACS Omega ISSN: 2470-1343
Scheme 1
Scheme 2
Scheme 3
Scheme 4
Figure 1Proposed intermediates D and E formed during the course of formation of 1–2 and 4–7, respectively.
Scheme 5
Scheme 6
Scheme 7
Figure 2Putative cycloplatinated guanidines anticipated to form in Scheme .
Scheme 8
Scheme 9
Figure 3Molecular structure of cis-[Pt(TFA)2(DMSO)2] at 50% probability level. Hydrogen atoms have been removed for clarity.
Figure 8Molecular structure of 12·CH2Cl2 at 50% probability level. The solvent molecule has been removed, and only hydrogen atoms of the amino moieties are shown for clarity.
Figure 9Possible geometrical isomers of 1–3.
Comparison of ρ Values of 1·1/2CH2Cl2, 3, 4, 7, [LH32-anisyl]TFA, 8, 10, 11·C7H8, and 12·CH2Cl2a
| complex | ( | ρ = 2 | |
|---|---|---|---|
| 1.309(5)/1.312(5) | 1.343(7)/1.352(7) | 0.97/0.97 | |
| 1.317(5)/1.314(5) | 1.324(7)/1.358(7) | 0.99/0.97 | |
| 1.305(8) | 1.337(12) | 0.98 | |
| 1.318(8) | 1.348(13) | 0.98 | |
| [LH32-anisyl]TFA | 1.337(2) | 1.338(3) | 1.00 |
| 1.295(9) | 1.356(13) | 0.97 | |
| 1.303(8) | 1.336(11) | 0.97 | |
| 1.303(7)/1.322(7) | 1.322(11)/1.338(10) | 0.99/0.99 | |
| 1.302(8)/1.301(8) | 1.330(11)/1.334(13) | 0.98/0.97 |
ρ = 0.93 (LH22-tolyl), 0.92 (LH22-anisyl) and 0.93 (LH22,4-xylyl).[42]
The values indicated are for the nonplatinated guanidine.
Figure 10Possible conformers of 10 and 11·C.
Figure 11Structural motifs of known cycloplatinated N-donor ligands.
Figure 12Possible conformers of 1–3 in solution. The substituents on the aryl rings have been removed for clarity.
Figure 13Interconversion of intermediates N and O via amine–imine tautomerization.
Figure 14Platinacycle 13 (Ar = 4-MeC6H4) which exists as a single isomer in solution.
Scheme 10
Figure 15Solvent-coordinated intermediates possibly formed in solution for 10 (P) and 11 (Q) in CDCl3 (Sol).